New drug targets liver cancer by starving tumors of arginine

NCT ID NCT05317819

Recruiting now Disease control Sponsor: Polaris Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery. Only people with high levels of the amino acid arginine in their blood can join. The goal is to see if the drug helps them live longer by breaking down arginine, which some cancers need to grow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Bach Mai Hospital
NOT_YET_RECRUITING

Hanoi, 100000, Vietnam
Chang Gung Medical Foundation-Chia-Yi (CGMF-CY)
RECRUITING

Chiayi City, 613, Taiwan
Chang Gung Medical Foundation-Kaohsiung(CGMF-KS)
RECRUITING

Kaohsiung City, 833, Taiwan
Chang Gung Medical Foundation-Linkou (CGMF-LK)
RECRUITING

Taoyuan, 333, Taiwan
Changhua Christian Hospital (CCH)
RECRUITING

Changhua, 500, Taiwan
Chi Mei Hospital, Liouying (CMMC-LY)
RECRUITING

Tainan, 736, Taiwan
Chi Mei Medical Center (CMMC-YK)
RECRUITING

Tainan, 710, Taiwan
Ditmanson Medical Foundation Chiayi Christian Hospital (CYCH)
RECRUITING

Chiayi City, 600, Taiwan
Hue Central Hospital
NOT_YET_RECRUITING

Huế, 49000, Vietnam
K Hospital
NOT_YET_RECRUITING

Hà Nội, 100000, Vietnam
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
RECRUITING

Kaohsiung City, 807, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.